Drug intelligence / Profile preview

Nasobol

Development stage: Phase 2
Lead developer: First Generation Capital
Modality: Small Molecules
Administration: Intranasal

Overview

Nasobol is an intra-nasal testosterone product developed by Acerus Pharmaceuticals Corporation. It is designed for testosterone replacement therapy, primarily indicated for hypogonadal men. The drug delivers testosterone directly via the nasal route to supplement deficient endogenous testosterone levels.

Brand names: Nasobol®

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Nasobol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nasobol.

Explore the full profile